144702-26-1

Basic information

• Product Name: 4'-[[1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl]-methyl]-1,1'-biphenyl-2-carboxylic acid 1,1-dimethylethyl ester
• Synonyms: 4'-1,4'-DIMETHYL-2'-PROPYL(2,6'-BI-1H-BENZIMIDAZOL)-1'-YL-METHYL-1,1'-BIPHENYL-2-CARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER;1,4'-DiMethyl-2'-propyl(2,6'-bi-1H-benziMidazol)-1'-yl -Methyl -1,1'-biphenyl-2-carboxylic acid 1,1-diMethylethyl ester;TelMisartan IMpurity C;TelMisartan tert-Butyl Ester;TelMisartan EP IMpurity C;[1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-diMethyl-2'- propyl[2,6'-bi-1H-benziMidazol]-1'-yl)Methyl]-,1,1- diMethylethyl ester;tert-butyl 4,-((1,7,-dimethyl-2,-propyl-1H,3,H-[2,5,-bibenzo[d]imidazol]-3,-yl)methyl)-[1,1,-biphenyl]-2-carboxylate;2-(4-{[4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl] methyl}phenyl)benzoic acid t-butyl ester
• CAS NO: 144702-26-1
• Molecular Formula: C₃₇H₃₈N₄O₂
• Molecular Weight: 570.72
• EINECS: 1533716-785-6
• Product Categories: Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 144702-26-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 780.446 °C at 760 mmHg
• Flash Point: 425.798 °C
• Appearance: White to off-white powder
• Density: 1.16
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 5.00±0.10(Predicted)
• CAS DataBase Reference: 4'-[[1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl]-methyl]-1,1'-biphenyl-2-carboxylic acid 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-[[1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl]-methyl]-1,1'-biphenyl-2-carboxylic acid 1,1-dimethylethyl ester(144702-26-1)
• EPA Substance Registry System: 4'-[[1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl]-methyl]-1,1'-biphenyl-2-carboxylic acid 1,1-dimethylethyl ester(144702-26-1)

Safety Data

• Hazardous Substances Data: 144702-26-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 144702-26-1 differently. You can refer to the following data:
1. Telmisartan tert-Butyl Ester is an impurity of Telmisartan (T017000). Telmisartan impurity C.
2. Telmisartan tert-Butyl Ester (Telmisartan EP Impurity C) is an impurity of Telmisartan (T017000). Telmisartan impurity C.

Upstream product

• 1190092-31-9 tert-butyl 4'-((6-formyl-4-methyl-2-n-propyl-1H-benzimidazol-1-yl)methyl)biphenyl-2-carboxylate 
• 612-28-2 2-nitro-N-methylaniline 
• 152628-01-8 4-butyrylamino-3-methyl-5-nitro-benzoic acid methyl ester 
• 675882-71-0 3-methyl-4-butyrylamino-5-aminobenzoic acid methyl ester 
• 152628-00-7 4-methyl-2-propyl-1H-benzimidazole-6-carboxylic acid methyl ester 
• 301533-59-5 methyl 4-(n-butyrylamino)-3-methylbenzoate 
• 152628-03-0 4-methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid 
• 25148-68-9 N-methylbenzene-1,2-diamine dihydrochloride 
• 18595-14-7 methyl 4-amino-3-methylbenzoate 
• 114772-40-6 4'-bromomethyl-biphenyl-2-carboxylic acid tert-butyl ester 
• 152628-02-9 2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole 

Downstream Products

• 144701-48-4 telmisatran 

Relevant articles and documents

Solid dispersions comprising Telmisartan and the preparation method thereof

The solid dispersions comprising telmisartan and a manufacturing method thereof, according to the present invention, unlike conventional methods requiring a low yield, can manufacture telmisartan of a high yield through simple and short steps by using a relatively inexpensive raw material, can secure excellent quality through reduction of generation of decomposition products, and can manufacture the solid dispersions on a mass production basis to be commercially available. Therefore, the solid dispersions of novel crystalline polymorph of the telmisartan of the present invention has improved storage stability and solubility, and can be synthesized at a high yield, thereby being expected to be very useful in the manufacture of pharmaceuticals.COPYRIGHT KIPO 2018

A modification to the synthesis of Telmisartan: An antihypertensive drug

A highly efficient approach to the synthesis of Telmisartan is described. Directed ortho-metalation of 4,4-dimethyl-2-phenyl-4,5-dihydrooxazole provided the key organozinc intermediate for a palladium catalysed biaryl coupling with 3′-(4-bromobenzyl)-1,7′-dimethyl-2′-propyl-1 H,3′ H-2,5′-bibenzo[d]imidazole which was obtained from alkylation of 1,7′-dimethyl-2′-propyl-1 H,3′H-2,5′-bibenzo[d] imidazole. This methodology overcomes many of the drawbacks associated with previously reported syntheses.

PROCESS FOR PREPARATION OF TELMISARTAN

A process for preparation of telmisartan comprises: (i) oxidation of compound of formula (a), wherein R2 is a hydrogen atom or a substituent of formula (b), in which R1 is a protecting group for the carboxyl function, to an aldehyde of formula (c), in which R2 is defined as in the formula (a), and, optionally, (ii) in case R2 in the compound (c) thus obtained is a hydrogen atom, iV-alkylation of the compound (c) with a biphenyl derivative, (iii) treatment of the compound (c) thus obtained with N- methyl- o-nitroaniline in a cyclocondensation reaction, and (iv) cleavage of the protecting group R1.